Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease Authors: Chandrashekhar Jori, Anas Ahmad, Ajay Kumar, Nemat Ali, Young-Ok Son, Rehan Khan Published: 2026 ABSTRACT AbstractOne of the major challenges in the treatment of inflammatory bowel disease (IBD) is the development of an oral drug delivery system that can provide extended GI residence time. In this work, a nanoformulation formed by Rebamipide (Re) encapsulated into mucin DEAE-dextran armored nanoparticles (M@D@Re-SCNPs) is introduced, which utilizes the core of caprylic acid (C)/6-O-stearoyl ascorbic acid (S). These M@D@Re-SCNPs were fabricated to provide both gastro-resistant and mucoadhesion properties of the nanoparticles. The M@D@Re-SCNPs showed pH-independent structural integrity in the gastric environment and proved to have a good mucosal binding capacity in the colon for long intestinal retention of up to 48 h. In terms of therapeutic efficacy, post-oral administration of M@D@Re-SCNPs strongly reduce the colon inflammatory status and the expression of inflammatory biomarkers like nuclear factor kappa B (NF-κB), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and phosphoinositide 3-kinase (PI3K) when compared with free rebamipide. The trapped rebamipide inhibits the production of pro-inflammatory mediators and promotes the production of mucin 2 (Muc2) protein, which promotes colon mucosal regeneration and goblet cell viability. Based on the necessity of controlling drug release and regulation of drug action for complete IBD treatment, we believe that the M@D@Re-SCNPs are a promising drug delivery system for UC treatment.Keywords: Ulcerative colitis, Mucin-based nanoparticles, Rebamipide, Inflammation, DEAE-Dextran biomucoadhesive Introduction IBD (ulcerative colitis (UC) and Crohn's disease (CD)) is a chronic inflammatory condition of the gastrointestinal tract, which causes a failure of the epithelial barrier, immune system dysregulation and chronic inflammation of the mucosa [1,2]. IBD is a growing problem in the world, impacting more than 6.8 million people worldwide and resulting in a significant burden of disease for health care [3]. A complex network of genetic susceptibility, environment, oxidative stress, microbial dysbiosis, and intestinal mucosal homeostasis are all involved in the pathogenesis of IBD [4,5]. Continued intestinal inflammation can lead to very serious consequences such as fibrosis, colorectal cancer and poor health, making it essential to find better treatment strategies. The current therapeutic approaches for IBD are primarily based on the use of corticosteroids, aminosalicylates, antibiotics, immunosuppressants and biologics [[6], [7], [8], [9]]. While these treatments can have a positive effect on the inflammation and induce a remission, their chronic efficacy is constrained by systemic side effects, the need for frequent dosing, lack of patient compliance and poor localization at the sites of inflammation in the intestine. The preferred route of administration is oral due to its convenience and non-invasiveness[[10], [11], [12], [13]]. Nevertheless, introduction of the drugs orally into the gastrointestinal tract is met with significant physiological hurdles, such as the presence of high levels of gastric acid, presence of enzymes, rapid gastrointestinal transit, mucus turnover and insufficient retention at inflamed sites in the colon[[14], [15], [16]]. Furthermore, diarrhoea-induced hypermotility also decreases the time spent in the gastrointestinal tract, resulting in suboptimal therapeutic responses [17,18]. For this reason, it is highly desirable to develop an oral drug delivery system with mucoadhesive and gastro-resistant characteristics that will allow for extended retention time in the intestine and provide effective treatment of IBD. Rebamipide is among emerging therapeutic candidates which have garnered significant interest due to its anti-inflammatory, antioxidant and mucosal protective activity [19,20]. Rebamipide has been clinically approved as a gastric ulcer therapeutic agent and has been demonstrated to promote goblet cell proliferation and mucin secretion and to inhibit inflammatory signaling pathways. However, these therapeutic benefits have not yet been appreciated in the use of rebamipide in colonic inflammatory disorders because of its low oral bioavailability and inadequate retention in the lower colon. For this reason, to enhance the stability, retention and sustained release at inflamed intestinal sites, an optimal nanocarrier system must be developed for an effective delivery of rebamipide. In the treatment of IBD, nanotechnology delivery systems have been shown to be potentially beneficial for targeting and enhancing mucosal adhesion of drugs derived from oral formulations [21,22]. In particular, diethylaminoethyl-dextran (DEAE-dextran), a positively charged polysaccharide derivative, has been reported to have high electrostatic affinity with the negatively charged inflamed colonic mucosa with high content in sialic acid residues [21,22]. This can greatly improve the adhesion of nanoparticles and their residence time at inflammatory sites. But DEAE-dextran-coated systems may suffer from premature degradation under acidic gastric environment and may reduce their oral delivery efficiency. To overcome this limitation, a number of mucin based protective coatings have recently been attracted due to their good biocompatibility and gastro protection performance [23,24]. Gastric mucin can serve as a temporary barrier to prevent degradation of nanoparticles in the stomach, while allowing their release in the intestine where there is a different pH profile, thus exposing the mucoadhesive layer. To develop an oral IBD therapy, we first designed a mucin (M)-armored DEAE-dextran (D) coated rebamipide (Re) loaded nanoparticles (M@D@Re-SCNPs). Caprylic acid (C) and 6-O-stearoyl ascorbic acid (S), the components of the nanoparticle (NP) core, are anti-inflammatory and antioxidant compounds, which are important in intestinal inflammation[[24], [25], [26], [27]]. The outer mucin layer was responsible for gastroprotection and the DEAE-dextran inner layer for the pH responsive mucoadhesion to inflamed colonic tissues. We hypothesized that this combinatorial approach would yield increased gastrointestinal stability, increase intestinal residence time, and increase the delivery of rebamipide to the gastrointestinal tract for effective treatment of colitis. Materials and techniques used in experiments Materials Gastric mucin (porcine, Type III, HiMedia, CAS 84082-64-4) was used as a high molecular weight (∼2–4 MDa) glycoprotein with ∼80% carbohydrate content. It contains O-linked oligosaccharides rich in GalNAc, GlcNAc, galactose, fucose, and sialic acid, and exhibits mucoadhesive properties relevant for drug delivery. DEAE-dextran (Sigma-Aldrich, Merck, MW ∼40 kDa, CAS 9015-73-0) is a cationic derivative of dextran with ∼10–20% diethylaminoethyl substitution. It is water-soluble, positively charged at physiological pH, and commonly used to enhance drug complexation and cellular uptake. Rebamipide (Re, TCI; CAS 90098-04-7), 6-O-Stearoyl ascorbic acid (TCI; CAS 10605-09-1) is a lipophilic ester of ascorbic acid and stearic acid, used as an amphiphilic antioxidant [26]. Its lipid solubility enhances membrane interaction and formulation stability. Caprylic acid (TCI; CAS 124-07-2), also known as octanoic acid, is a medium-chain saturated fatty acid with amphiphilic properties [24]. It functions as penetration enhancer in lipid-based and drug delivery systems. Alcian blue, Toluidine blue, Griess Reagent and N-methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide system were purchased from Alfa Aesar. Primary antibodies NF-kB p65, PARP-γ, MIP-1α, and MUC 2 were purchased from cloud clone. Potassium chloride (KCl), sodium chloride (NaCl), potassium dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate (Na2HPO4), and paraformaldehyde etc. were purchased from Himedia Laboratories. All standard chemicals employed in this study were of high-quality research or analytical grade. Methods Preparation and synthesis of mucin/DEAE-dextran armored M@D@Re-SCNPs To prepare rebamipide-loaded anionic nanoparticles (Re-SCNPs), rebamipide was added to a mixture of 6-stearoyl ascorbic acid and caprylic acid, which were dissolved in a 4:1 (w/w) ratio using a chloroform:methanol (2:1, v/v) solvent system. The solvent was then evaporated under reduced pressure using a rotary evaporator to form a thin lipid film. The dried film was hydrated with PBS (pH 7.4) sonication (probe sonicator, 30% amplitude) to obtain a homogeneous nanoparticle suspension. Unencapsulated rebamipide was removed by centrifugation (15,000 rpm, 30 min, 4°C), and the resulting Re-SCNPs were characterized further. For DEAE-dextran (D) coating, the purified Re-SCNPs (1 mg/mL in PBS) were incubated with DEAE-dextran solution (2 mg/mL in PBS) at a 1:1 (w/w) ratio under gentle stirring (300 rpm, 1–2 h, RT). Unbound DEAE-dextran was removed by centrifugation (15,000 rpm, 30 min, 4°C), and the coated nanoparticles (D@Re-SCNPs) were resuspended in PBS for further characterization and stability studies. Successful coating was confirmed by zeta potential analysis and lyophilized. In order to armor the D@Re-SCNPs with mucin, 1% (w/v) mucin was slowly added into the 1:1 ratio of the D@Re-SCNPs blend and stirred slowly at 700 rpm for 120 min. Finally, mucin/DEAE-dextran armored rebamipide loaded nanoparticles (M@D@Re-SCNPs) collected by centrifugation and uncoated mucin, i.e. D@Re-SCNPs, were removed. Furthermore, M@D@Re-SCNPs (Table ST1-3) was characterized by their shape and more characterization factors as follows. Characterization methods Techniques The hydrodynamic diameter, polydispersity index (PDI), and zeta potential of blank SCNPs and rebamipide-loaded M@D@Re-SCNPs (n = 3) were measured at 25°C using dynamic light scattering (DLS) and Phase Analysis Light Scattering (PALS) techniques with a Zetasizer Nano ZSP (Model ZEN5600; Malvern Instruments Ltd., UK). Each measurement was performed in triplicate. Fourier Transform Infrared (FTIR) spectra of Rebamipide, DEAE-dextran, Mucin, 6-stearoyl Ascorbic Acid, Caprylic Acid, and M@D@Re-SCNPs (5 mg each) were recorded using a Cary Agilent 660 spectrophotometer over 400–4000 cm−1 with 256 scans at 4 cm−1 resolution. For morphological assessment, Field Emission Scanning Electron Microscopy (FESEM) was conducted using a JEOL JSM-7600F microscope after drop-casting aqueous samples onto silicon wafers and drying overnight. Transmission Electron Microscopy (TEM) was performed using a JEOL JEM-2100 microscope operated at 120 kV; samples were prepared by drop-casting aqueous suspensions on carbon-coated copper grids and air-drying overnight. Detailed protocols of techniques and release kinetics protocols are provided in the Supporting information. Cytocompatibility of M@D@Re-SCNPs The cytocompatibility of M@D@B-SCNPs (rebamipide-free) and M@D@Re-SCNPs (with rebamipide) was evaluated using the MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) on immortalized normal human foreskin fibroblasts (hTERT-BJ) and Caco-2 cells, following previously established methods [28]. Briefly, cells were seeded at a density of 1 × 104 cells per well in a 96-well culture plate and exposed to varying concentrations of M@D@B-SCNPs and M@D@Re-SCNPs (with rebamipide) for 24 and 48 h. Cell viability was measured using the EZcount™ MTT Cell Assay Kit (Himedia) per the manufacturer's guidelines. After 3–4 h of incubation with MTT solution, 100 μL of solubilization buffer was used to dissolve the resultant formazan crystals. An ELISA plate analyzer was used to measure absorbance at 590 nm to determine the percentage of viable cells. Cell viability of untreated control cells was considered 100% for normalization. Assessment of anti-inflammatory activity of M@D@Re-SCNPs The anti-inflammatory potential of M@D@Re-SCNPs was investigated using a lipopolysaccharide (LPS)-induced inflammation model in vitro. To develop an inflammatory cellular model, RAW 264.7 cells were stimulated for 24 h with LPS (1 μg/mL); afterwards, anti-inflammatory therapeutic activity of the different nanoparticle formulations was evaluated. An inflammatory marker, nitrite formation, was quantified using the Griess reagent, with absorbance measured at 540 nm [26]. This assay enabled the evaluation of the M@D@Re-SCNPs effectiveness in reducing inflammation by determining their impact on nitrite levels in the LPS-induced inflammatory response. Efficacy of M@D@Re-SCNPs on dextran sodium sulfate induced colitis Animal ethical statement All experiments were carried out in accordance with applicable legal standards, institutional regulations, and the ARRIVE guidelines [29]. 6–8 week-old female Swiss albino mice weighing 20–30g were obtained from the Central Animal Facility (CAF), NIPER, Mohali. They had unlimited access to water, and a typical mice pellet diet. The Indian Institute of Science Education and Research, Mohali (IISER Mohali), the Committee for Purpose of Control and Supervision on Experimental Animals (CPCSEA), India, has granted it full accreditation, approved the use of animals in all of its experiments. The project number for approval is IISERM/SAFE/PRT/2023//008. Evaluation of M@D@Re-SCNPs in a DSS-induced colitis model The therapeutic effects of M@D@Re-SCNPs were assessed using dextran sulfate sodium (DSS)-induced colitis model. A total of 36 mice were randomly allocated into six groups, each comprising six animals, as outlined in Fig. S4. Experimental design for DSS-induced colitis model and treatment groups The experimental setup involved six groups of Swiss albino mice (n = 6 per group), as detailed below: •Group 1 (Control, i.e. healthy): The mice were fed a typical baseline diet without any treatment and served as control. Group 1 (Control, i.e. healthy): The mice were fed a typical baseline diet without any treatment and served as control. •Group 2 (DSS colitic model): For five days, mice were supplied 4% w/v DSS in drinking water ad libitum, (ad.lib.) in order to induce colitis. Group 2 (DSS colitic model): For five days, mice were supplied 4% w/v DSS in drinking water ad libitum, (ad.lib.) in order to induce colitis. •Group 3 (DSS + M@D@Re-SCNPs, Treatment group): Colitis-induced mice were treated with M@D@Re-SCNPs at an equivalent dose corresponding to 100 mg/kg body weight of Re [30], administered orally (p.o.) via gavage for five alternate days post-induction of colitis to evaluate the better therapeutic effect of M@D@Re-SCNPs against the colitis. Group 3 (DSS + M@D@Re-SCNPs, Treatment group): Colitis-induced mice were treated with M@D@Re-SCNPs at an equivalent dose corresponding to 100 mg/kg body weight of Re [30], administered orally (p.o.) via gavage for five alternate days post-induction of colitis to evaluate the better therapeutic effect of M@D@Re-SCNPs against the colitis. •Group 4 (DSS + Rebamipide, Free Re): Colitis-induced mice received a 100 mg/kg body weight dose of free Re, administered orally (p.o.) [30] via gavage for five alternate days post-induction of colitis to evaluate the therapeutic effect of naïve rebamipide against the colitis. Group 4 (DSS + Rebamipide, Free Re): Colitis-induced mice received a 100 mg/kg body weight dose of free Re, administered orally (p.o.) [30] via gavage for five alternate days post-induction of colitis to evaluate the therapeutic effect of naïve rebamipide against the colitis. •Group 5 (DSS + M@D@B-SCNPs, blank nanoparticles without Re): Colitis-induced mice, an equal dosage was administered orally (p.o.) of M@D@B-SCNPs, via gavage for five alternate days to evaluate the efficacy of M@D@B-SCNPs in DSS-induced colitis mice model. Group 5 (DSS + M@D@B-SCNPs, blank nanoparticles without Re): Colitis-induced mice, an equal dosage was administered orally (p.o.) of M@D@B-SCNPs, via gavage for five alternate days to evaluate the efficacy of M@D@B-SCNPs in DSS-induced colitis mice model. •Group 6 (Control + M@D@B-SCNPs, Safety group): Healthy mice were treated with an equal dosage administered orally (p.o.) of M@D@B-SCNPs via gavage for five alternate days for evaluation of the toxicity towards vital organs such as the heart and spleen, kidney, lungs and liver. Group 6 (Control + M@D@B-SCNPs, Safety group): Healthy mice were treated with an equal dosage administered orally (p.o.) of M@D@B-SCNPs via gavage for five alternate days for evaluation of the toxicity towards vital organs such as the heart and spleen, kidney, lungs and liver. Colitis model induction in mice Swiss albino mice were used to develop ulcerative colitis by administering DSS (4% w/v) in unrestricted drinking water (ad.lib.) for 5 days. Five days after DSS therapy, stool consistency, physical activity, and rectal haemorrhage examination were used to measure colonic inflammation, confirming the establishment of colitis [31]. Assessment of physical parameters An indicator of disease activity was created considering factors like body weight loss, blood in the stool via fecal occult blood test (FOBT), and stool consistency to evaluate the degree of inflammation in mice caused by DSS. One important factor that was assessed was colon shortening, which is a symptom of severe inflammation. Post-sacrifice assessment of colon length allowed for the evaluation of anti-inflammatory activity of Re and M@D@Re-SCNPs, facilitating quantification of inflammation severity and assessment of therapeutic interventions. Histological, immunohistochemical, and biochemical assessments To preserve cellular structure and morphology, the colons and vital organs, including the heart, kidneys, lungs, spleen, and liver, were promptly immersed in 10% neutral buffered formalin for 24 h following euthanasia. Following fixation, the tissues were embedded in paraffin and sectioned into thin slices (5 μm thick) using a microtome. Histological evaluations of colonic tissues (5 μm thick) were conducted using Hematoxylin and Eosin (H&E) staining to assess epithelial damage, crypt abscesses, and inflammation, and Alcian Blue–Neutral Red (AB-NR) staining to visualize goblet cell depletion and mucosal integrity. High Iron Diamine–Alcian Blue (HID-AB) staining was performed to differentiate mucin types and investigate goblet cell dynamics under inflammatory conditions. Mast cells were identified using toluidine blue staining. Immunohistochemical analysis was conducted to detect the expression of NF-κB p65, PARP-γ, MIP-1α, and MUC2 in paraffin-embedded colonic sections using specific primary antibodies and HRP-conjugated secondary antibodies, followed by hematoxylin counterstaining. Myeloperoxidase (MPO) activity, an index of neutrophil infiltration, was quantified in colon tissue homogenates and expressed as U/g protein. Nitrite levels, indicative of nitric oxide production, were determined using the Griess reagent with absorbance measured at 540 nm. Total protein concentration in tissue homogenates was measured using the Bradford assay with BSA as the standard. Detailed protocols for each procedure are provided in the Supporting Information. M@D@Re-SCNPs prolonged in vivo GI residence abilities Evaluation of adhesion properties of M@D@Re-SCNPs using DiR fluorescent dye In vivo mucoadherence studies, the fluorescent dye DiIC18 (7) (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide, DiR) was used as a substitute for M@D@Re-SCNPs. The mice were separated up into two groups: a control group and a DSS-induced colitis group, where colitis was induced using DSS. DiR-loaded M@D@SCNPs was administered orally, and fluorescence in the colon was analyzed post-euthanasia. This experimental design facilitated both in vivo and ex vivo assessment of the mucoadhesion properties of M@D@Re-SCNPs, providing important information on how they interact with colonic mucosa in both healthy and colitis-related circumstances [32]. Single cell suspension of Gut Associated Lymphoid Tissue (GALT) (lamina propria and intraepithelial lymphocytes) from colons In the study of gut immunity and its role of the M@D@Re-SCNPs in colitis mice, the experiment isolates and analyzes immune cells from gut-associated lymphoid tissue (GALT) in the colon, focusing on lamina propria (LP) and intraepithelial lymphocytes (IELs). Mechanical disruption and enzymatic digestion release cells, characterized by flow cytometry using specific surface markers. This enables immune cell subset identification, quantification, and functional profiling. Detailed protocol is provided in the Supporting information. Statistical analysis GraphPad Prism (GraphPad Software, San Diego, CA, USA) was used to analyze the data. An unpaired Student's t-test was used for comparisons between two groups. For differences between two or more groups a One-way ANOVA was used with Bonferroni's post hoc test for multiple comparisons. Statistical significance was set at ∗P < 0.05, ∗∗P < 0.01, ∗∗∗/###P < 0.001, and ∗∗∗∗/####P < 0.0001. Results and discussion Preparation of mucin-coated DEAE-dex layered rebamipide-loaded nanoparticles M@D@Re-SCNPs In this investigation, we developed mucoadhesive and gastroprotective nanoparticles (SCNPs) by thin film hydration and layer-by-layer coating (Fig. 1A). Using the thin film hydration process, the pillars of SCNPs were fabricated by utilizing antifungal, antibacterial, and anti-inflammatory caprylic acid (C) and antioxidant 6-stearoyl ascorbic acid (S). The purpose of this research was to create SCNPs that included the anti-ulcerative and anti-inflammatory drug rebamipide (Re-SCNPs) Fig. 1A. In order to improve mucoadhesion and gastroprotection, the Re-SCNPs were coated with cationic DEAE-dextran (D@Re-SCNPs) after interaction with anionic gastric mucin (M@D@Re-SCNPs), as shown in Fig. 1B. Fig. 1C shows the hypothetical representation of the therapeutic efficacy of the M@D@Re-SCNPs against the colitis model. ) A & B) Preparation of mucin-coated DEAE-dextran layered rebamipide-loaded nanoparticles (M@D@Re-SCNPs) and C) oral administration M@D@Re-SCNPs as a combined therapy against colitis through the restoration of intestinal barriers, reduced proinflammatory cytokine levels, and the upregulation of gut mucin homeostasis. Characterization of nanoparticles (SCNPs, D@Re-SCNPs and M@D@Re-SCNPs) A single factor experimental design was used to determine the optimum composition of the nanoparticles by changing the proportion of 6-O-stearoyl ascorbic acid and caprylic acid, while measuring the particle size, PDI, zeta potential and encapsulation efficiency of the nanoparticles. The formulation with 4:1 ratio showed the most optimum physicochemical properties as it had smaller particle size, narrow size distribution and high encapsulation efficiency and colloidal stability, which is most suitable for oral delivery applications (Table ST1-3). DLS was initially utilized to assess the size and polydispersity index (PDI) of blank SCNPs and rebamipide-loaded SCNPs (Re-SCNPs). DLS measurement analysis exhibits 160 ± 3.39 nm, 200 ± 8.66 nm, and 220 ± 15.73 nm of hydrodynamic diameter (particle size) for SCNPs (nanoparticles), D@SCNPs (DEAE-dextran coated nanoparticles), and M@D@SCNPs (mucin layered DEAE-dextran coated nanoparticles) respectively, due to layer-by-layer coating. Upon incorporating rebamipide (Re) into nanoparticles (Re-SCNPs) and subsequently coating them with DEAE-dex (D@Re-SCNPs), followed by mucin (M@D@Re-SCNPs), the mean hydrodynamic diameter exhibits increments to 200 ± 5.60 nm, 233 ± 3.27 nm, and 260 ± 1.92 nm, respectively (Fig. 2A and B, Figure S1). Moreover, Re-SCNPs, D@Re-SCNPs, and M@D@Re-SCNPs display monodispersity, as shown by polydispersity index (PDI) values of 0.314, 0.248, and 0.163 which suggest the lack of agglomeration formation. Zeta potential analysis showed a change from negative (Re-SCNPs −28.9 ± 0.51 mV) to positive (D@Re-SCNPs +38.43 ± 0.46 mV), which may be attributed to DEAE-dextran's positively charged amino groups. This indicates that DEAE-dextran has been coated on the particle surface (D@Re-SCNPs). The formation of M@D@Re-SCNPs by subsequent anionic coating with gastric mucin was confirmed by a zeta potential measurement of −20.1 ± 1.30 mV (Fig. 2A and B). FTIR spectroscopy was employed to verify the chemical structure, component integration, and successful surface modification of the M@D@Re-SCNPs. The FTIR spectrum of DEAE-dextran displayed characteristic absorption bands at approximately 3400 cm−1, attributed to O–H and N–H stretching vibrations, along with peaks at 2920 cm−1 (C–H stretching), 1650 cm−1 (N–H bending), and 1450 cm−1 (C–N stretching). Mucin exhibited distinct peaks near 3400 cm−1 (O–H/N–H), 1630 cm−1 (amide I), 1530 cm−1 (amide II), and 1050 cm−1, corresponding to the glycoprotein backbone's C–O–C stretching. The core lipids, 6-O-stearoyl ascorbic acid and caprylic acid, showed signature ester and fatty acid functional groups. Specifically, 6-O-stearoyl ascorbic acid presented strong absorption at 1735 cm−1 (C=O ester), 2920 cm−1 (CH2 stretching), 1450 cm−1 (C–H bending), and 1150 cm−1 (C–O stretching). Caprylic acid displayed absorption bands at 1700 cm−1 (C=O stretching), 2920/2850 cm−1 (alkyl chain stretching), and 930–950 cm−1 due to alkyl vibrations. For rebamipide, prominent FTIR features were observed at 1650 cm−1 for the amide C=O stretch, with broader bands near 3400 cm−1 related to NH/OH stretching, and additional signals at 1590 cm−1 and 1490 cm−1 indicating aromatic ring vibrations. In the composite M@D@Re-SCNPs spectrum, several characteristic peaks of individual components were retained, though shifts in peak positions and intensity changes were noted. The combined and altered spectral features confirm the successful encapsulation of rebamipide and the layered assembly of mucin and DEAE-dextran onto the nanoparticle surface (Fig. 2C). According to the UV-vis spectroscopy measurement, the drug loading was around 18 ± 0.01% and the encapsulation effectiveness was about 95 ± 0.07% which is impeccable for a rebamipide delivery (Fig. 2D). Given that the M@D@Re-SCNPs are intended for delivering medication regionally on the gastrointestinal membrane, the nanoparticles composition must be stable for sufficient time to gain access to the mucosa that is inflammatory and be disintegrated by the inflammatory cascades near the inflamed colon. The morphology of SCNPs and M@D@Re-SCNPs was evaluated using TEM and FESEM. Both analyses confirmed that the nanoparticles were nearly spherical, monodisperse, and free of agglomeration. SCNPs exhibited an average size of approximately 160 nm, while M@D@Re-SCNPs showed a size increase to around 260 nm, attributed to the sequential coating with DEAE-dextran, gastric mucin, and rebamipide loading. The TEM images further confirmed the successful layering of these materials on the nanoparticle surface (Fig. 2Ea & b). ) Characterization of nanoparticles (SCNPs, D@Re-SCNPs and M@D@Re-SCNPs), Nanoparticles zeta potential and mean hydrodynamic particle size observations. A) Blank SCNPs, D@SCNPs, and M@D@SCNPs, B) Rebamipide-loaded SCNPs, D@Re-SCNPs and M@D@Re-SCNPs, C) FTIR analysis of the DEAE-dextran, Mucin, 6-steroyl ascorbic acid, Caprylic acid, Rebamipide, and M@D@Re-SCNPs identified the vibrational frequencies, D) Encapsulation and rebamipide loading efficiency in M@D@Re-SCNPs (n = 3, mean ± SD), E) Morphological evaluation via FESEM and TEM of E.a) SCNPs and E.b) M@D@ReSCNPs. Biocompatible, digestive enzyme-resistant, in vitro drug release kinetics, cytocompatibility and anti-inflammatory activity We then gazed at the impact of the chemical environment on the gastrointestinal (GI) tract, which includes intestinal fluid and gastric acid, as well as the physiological procedure of peristalsis. To evaluate the pH-responsive disintegrating properties, we incubate the samples first in 1.2 pH simulated gastric fluid (Ga) and then in 6.8 pH PBS. We have used FESEM and TEM photomicrographs to assess the structural alterations. After SCNPs were incubated for 2 h at the pH 1.2 Ga, observable modifications in their structure and integrity were evident. Conversely, M@D@Re-SCNPs, post-coating, exhibited no discernible changes in morphology, maintaining a stable spherical shape and integrity at pH 1.2 (Fig. 3A). On the other hand, at the simulated intestinal fluid (In) pH 6.8, SCNPs began to lose their form after just 2 h, while M@D@Re-SCNPs started to swallow and disintegrate the mucin layer in 1 h. The DEAE-dextran coating layer swelled in an alkaline environment [33], increasing nanoparticle size. The M@D@Re-SCNPs slowly started to lose their shape and integrity after 4 h of incubation in simulated intestinal fluid, which would result in the cargo release (Fig. 3B). These findings indicated the gastroprotective efficacy of M@D@Re-SCNPs and cargo released in the specific inflamed colon vicinity, which is crucial for oral nanoformulation. Re-SCNPs and M@D@Re-SCNPs were utilized in vitro rebamipide release experiments under simulated gastric and gastrointestinal conditions. In Ga, Re-SCNPs demonstrated rapid rebamipide dissolution and rate of release within 2 h. In Re-SCNPs, the rebamipide was enclosed in a lipid-polymer matrix that may disintegrate quickly in an acidic environment. The release kinetics of free rebamipide were utilized for comparison with Re-SCNPs. The release kinetics indicated a slight delay in rebamipide release from Re-SCNPs compared to free rebamipide. This slower release observed in Re-SCNPs can be attributed to the encapsulation of rebamipide within the nanoparticle core, which is composed of 6-stearoyl ascorbic acid and caprylic acid. These core components create a barrier that moderates the diffusion of rebamipide; resulting in a slightly delayed release profile compared to free rebamipide i.e. Re-SCNPs was also unstable in the gastric environment. In M@D@Re-SCNPs, the release profiles demonstrated that in all samples, the DEAE-dextran and mucin coating thwarted drug release at the Ga (pH 1.2). It again confirms the gastroprotective behaviour of M@D@Re-SCNPs. There were notable variations in the rebamipide release behaviour at inflamed colonic pH 6.8 [34], with a slow release continuing for 4 h, as demonstrated in Fig. 3C. Consequently, the release of Re from M@D@Re-SCNPs was extended for up to 84 h, and about 80% of the Re was released from M@D@Re-SCNPs in 84 h (Fig. 3C). When treating IBD, a controlled release of drugs is preferred as it offers an advantage in reaching the appropriate concentration needed for targeted action and sustaining it for an extended amount of time within the intestine or colon. Further in vitro release measurements were conducted in the absence and presence of β-glucosidase enzyme in different gastrointestinal and colonic pH mediums to assess the pH-responsive and enzyme-triggered release profile of M@D@Re-SCNPs (Fig. S3). The nanoformulation showed very low release of rebamipide when pH was 5.0 and 5.5, while the release was gradually accelerated and sustained with the increase in pH. Interestingly, at the pH 6.8 (closely resembling the inflamed colonic environment) the maximum cumulative drug release was observed. In addition, the presence of β-glucosidase significantly promoted the release of rebamipide at all the investigated pH values, suggesting that the coated layers were degraded under the influence of the enzyme, resulting in the release of the cargo under the simulated colonic microflora conditions. The present results further confirm the gastrointestinal stability, colon-targeted release capacity and extended therapeutic potential of M@D@Re-SCNPs in oral therapy of IBD. M@D@B-SCNPs (without Re) and M@D@Re-SCNPs were screened for cytocompatibility against normal hTERT-BJ (human skin fibroblast BJ) cells and Caco-2 cells at 24- and 48-h intervals to make sure the healthy cells weren't being impacted by the biomaterial. Based on the non-significant change in cell viability, we noticed that both nanoparticles till 200 μg/mL dosage were not damaging, cytocompatible to hTERT-BJ and Caco-2 cells and had negligible effects (Fig. 3D and F). Alternatively, at an elevated concentration of 400 μg/mL at both time points, there was a marginal decline in cell viability observed, although this reduction was not statistically significant. Our results showed that a dosage of up to 200 μg/mL of nanoparticles could be considered safe for normal cells. Using lipopolysaccharide (LPS), an understood inflammatory response trigger via TLR-4 receptor activation, RAW264.7 cells underwent stimulation to analyze the anti-inflammatory potential of Re only, M@D@B-SCNPs (without Re) and M@D@Re-SCNPs. After subjecting cell lines to a 1 μg/mL dosage of the LPS, different doses of free Re, M@D@B-SCNPs, and M@D@Re-SCNPs were added to inflammatory response cells. Notably, treatment with M@D@Re-SCNPs showed a dose-dependent decrease in nitrite levels significantly decreased than in the group treated with free Re and M@D@B-SCNPs (Fig. 3E). This implies that after being encapsulated in M@D@Re-SCNPs, Re's therapeutic effectiveness may have improved, with the benefit of obtaining an efficient drug for treating inflammatory conditions at lower dosages. Anti-inflammatory activity of M@D@Re-SCNPs was analyzed in vitro by measuring the levels of cytokines of LPS activated RAW264.7 cells. The results showed that M@D@Re-SCNPs significantly down-regulated the expression of the inflammatory cytokines, such as TNF-α and interleukin-6 (IL-6) (Fig. 3G and H). ) Rebamipide release kinetics, biocompatibility, and resistance to digestive enzymes: FESEM and TEM photomicrographs of SCNPs and M@D@Re-SCNPs after immersion in A) Simulated gastric fluid (pH 1.2,Ga) up to 2 h, and B) simulated intestinal fluid (pH 6.8, In) up to 2 h (SCNPs) and, 1h and 4h (M@D@Re-SCNPs). C) In-vitro rebamipide release kinetics, a) In simulated gastric fluid (Ga), release profiles of free rebamipide and rebamipide-loaded SCNPs (Re-SCNPs) without DEAE-dextran and mucin coatings. Both exhibited a rapid release of rebamipide over the initial period (within 2 h) of the study, indicating the quick dissolution and diffusion of the rebamipide from the nanoparticle core, b) Primed rebamipide was released over an extended period of time through M@D@Re-SCNPs (n = 3, mean ± SD). Biocompatibility and anti-inflammatory studies D and F) The MTT assay's cytocompatibility of M@D@B-SCNPs (Blank SCNPs), M@D@Re-SCNPs (with rebamipide) and free rebamipide at normal hTERT-BJ and Caco-2 cell line respectively. E) The anti-inflammatory activity of naïve Rebamipide and M@D@B-SCNPs against cell line (activated RAW 264.7) was evaluated by taking measurements of nitrite levels. Enzyme-linked immunosorbent assay (ELISA) results showing the extracellular expression of G) TNF-α, H) IL-6. The results were provided as three separate observational sets (as mean ± SD), and three replicates of the experiments were carried out. Significant changes were indicated by ∗p ≤ 0.05, ∗∗p ≤ 0.01, and ∗∗∗p ≤ 0.001; respectively. Therapeutic effect of M@D@Re-SCNPs against IBD model M@D@Re-SCNPs for effective treatment of colitis We looked into whether M@D@Re-SCNPs could alleviate colitis in vivo despite the encouraging in vitro conclusions for stopping cascades of inflammation. Mouse model of Dextran Sodium Sulfate (DSS)-colitis was chosen to conduct further in-vivo studies. Six groups were selected at random from all of the mice: Control (healthy), 4% DSS (colitis model), DSS + M@D@Re-SCNPs, DSS + Rebamipide (Re), DSS + M@D@B-SCNPs (without Re), Control + M@D@B-SCNPs. All groups of mice received the appropriate medications by oral gavage, as shown in Fig. 4A. We assessed recovery of body weight, and Fig. 4B and C illustrated that the mice given treatments were considerably prevented from the weight loss caused by DSS. In this research, mice without colitis had normal feces, while diarrhoea and bleeding were seen in colitis mice. Treatment with M@D@Re-SCNPs brought these signs back to normal, significantly decreasing the diarrhoea and bleeding than naïve Rebamipide (Re). Naive Re decreased bleeding while keeping stools loose. Stool consistency returned to normal by M@D@Re-SCNPs. Colitis brought on by DSS reduced physical movement and resulted in occult blood in the stool. Interestingly, M@D@Re-SCNPs enhanced activity and considerably lowered occult blood than naïve Re treated group. Using the FOBT kit, faecal occult blood was qualitatively evaluated; in mice with colitis that received no treatment, the presence of blood was indicated by a blue stain. The treatment of M@D@Re-SCNPs diminished occult blood (Fig. 4D), and Re showed in a light blue color stain. All FOBT scoring (mean ± SD, n = 6) was quantified in Fig. 4E and Table ST4). Mice treated with DSS, naive Re, and M@D@B-SCNPs showed significant intestine length decreases in comparison to those receiving M@D@Re-SCNPs treatment and quantified in Fig. 4F and G. As all taken together, these findings indicated that oral M@D@Re-SCNPs treatment was very effective in treating colitis disease. ) M@D@Re-SCNPs for efficient DSS-Colitis mouse model therapy, A) Experimental protocol showed for DSS-induced colitis model with oral administration of M@D@Re-SCNPs. B) Study of weight of experimental animal body variation percentage and C) Weight of experimental animal body ratio measurements from several groups with colitis group. Performed by repeated measures ANOVA, significant differences were denoted by ∗p ≤ 0.05; ∗∗p ≤ 0.01; and ∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001 respectively-E) Assessment of FOBT strip experiment and quantitative score from feacal samples. F-G) Representative images were showing colon length evaluations in various treatment groups (mean ± SD, n = 6), Significant differences were denoted by ∗/#p ≤ 0.05; ∗∗/##p ≤ 0.01; and ∗∗∗/###p ≤ 0.001, ∗∗∗∗/####p ≤ 0.0001 respectively. M@D@Re-SCNPs prolonged in vivo gastrointestinal residence abilities We anticipate that our mucoadhesive and spherical M@D@Re-SCNPs can adjust to the GI tract's fluid content, complex motility and sharp pH variation and form a long-lasting, large-area coating on the intestinal mucosa that ensures enough intestinal holding for prolonged drug release. Since inflamed colonic mucus contains negatively charged sialic acid substructures, DEAE-dextran's positively charged primary amines interact with them to provide targeted and facile colonic absorption. Due to microbial enzymatic degradation [35], the mucin layer of M@D@Re-SCNPs at the inflammatory site becomes disrupted, exposing the cationic DEAE-dextran surface, which adheres to the inflammatory colitis area by electrostatic interaction. This notion was further tested by assessing in vivo M@D@Re-SCNPs propensity to behave as biomucoadhesive coatings on the gastrointestinal mucosa. Control and DSS group mice were given a single oral gavage of M@D@DiR-SCNPs (modified with DiR fluorescent dye) to assess the fluorescence retention in the extracted GI tract. The mice were sacrificed after 0, 6, 24, and 48 h. The M@D@DiR-SCNPs in the DSS group stalled in the mice's GI tract for at least 48 h, as shown by the strong fluorescence signal consistent with the in-vitro biomucoadhesive characteristic. On the other hand, in the control group, after one day, the M@D@DiR-SCNPs showed minimal holding in the GI tract, as shown by the quantified fluorescence intensity (Fig. 5A and B). Regular stomach emptying occurs in 2 h, while colonic arrival usually occurs in 5 h in humans [36]. Thus, our M@D@DiR-SCNPs were shown to be retained in the gastrointestinal tract for a long time in the in vivo intestinal retention assays. One of the most essential aspects of oral nanomedicine for treating colitis is their ability to withstand the harsh conditions of the gastrointestinal tract and to remain stalled sufficiently long in the colon. To reach the colon, armored M@D@Re-SCNPs successfully resisted the gastric and intestinal environmental conditions. Additionally, the negatively charged surface of the Re-SCNPs and M@D@Re-SCNPs allows them to adhere to the positively charged proteins seen in an inflammatory colon like antimicrobial peptides and transferrin that employs covalent linkage, hydrogen bonding, cation-π interaction, and electrostatic interaction to interact with colitis inflamed colonic site [37] (Fig. 5C). ) M@D@Re-SCNPs extended in-vivo gastrointestinal (GI) residence: A) Biomucoadhesive M@D@Re-SCNPs administered by orally was retained for a minimum of 48 h in the DSS-induced colitis mice, while the control group showed up to 24 h retention time. B) Quantification of fluorescence intensity (n = 3, mean ± SD). C) M@D@Re-SCNPs nanomedicines long-term adsorption capacity in the inflammatory colon and mechanism of action. The profound effect of M@D@Re-SCNPs on GALT This study examined M@D@Re-SCNPs about perturbations in the neutrophil, macrophage, B cells and T cells population in Gut Associated Lymphoid Tissue (GALT). The colons of several mouse groups were examined for intraepithelial and lamina propria cells. It is commonly known that T-helper cells and interleukin-6 both release interleukin-9. Th2 and Th9, proinflammatory neutrophil cells that particularly release interleukin-17, monocytes, NK cells, Th17 proinflammatory cells, and T cells (CD8+) [38]. Increased putative macrophage population, helper T cells, and dendritic cells (DCs) are also at the forefront of proinflammatory cytokines secretion, including TNF-α and interleukin-23 [39]. Our data also demonstrated higher neutrophil fractions in lamina propria and intraepithelial cells, supporting the preceding findings and enhancing our M@D@ Re-SCNPs ability to address inflammation in experimental colitis. In addition to the colons lamina propria, the experimental colitis group's intraepithelial lymphocytes (IEL) cellular fractions also showed an elevated neutrophil proportion. The treatment in colitis mice with M@D@Re-SCNPs resulted in an enormous reduction of the percentage of the neutrophils in lamina propria as well as IEL (Fig. 6A, B, 6C, and 6G, 6H, 6I) and quantified in Figure S9. In the gastrointestinal system during homeostasis, leukocytes identified as eosinophils, with the exception of the oesophagus, which normally has.no eosinophils. Furthermore, eosinophils were assessed a few years ago as essential cells that support immune cell infiltration in IBD. This was illustrated, for instance, by the Geboes histological UC score, which indicates the infiltration of eosinophils in the lamina propria [40]. A feature in the initial identification of IBD is basal plasmacytosis associated with eosinophilia, which strongly correlates with the histological diagnosis. Likewise, the strongest indicator of a poor response to medical therapy in patients with ulcerative colitis is significant eosinophil infiltration in the population of several proinflammatory cell types altered in ulcerative colitis. These cells include dendritic cells, the lamina propria of colonic biopsies, and proinflammatory macrophages that secrete interleukin-1β [41]. ) Therapeutic effect of M@D@Re-SCNPs of isolated myeloid cell subtypes and lymphoid cells from the colon lamina propria and IELs: Evaluation of the various myeloid cell types extracted from the mice colon in distinctive treatment groups from the lamina propria, Quantitative evaluation of A) The target cell population, Neutrophils were identified as CD11b+Ly6G+ cells within the CD11c^low^ myeloid compartment. B) Representative FACS panels are used to evaluate putative macrophages population (MHC-II+SiglecF+ myeloid cells) and C) The population of dendritic cells in lamina propria tissues are characterized as SiglecF- and MHC Class II+.D) Representative FACS analyzed data for helper T cells i.e. CD4+ cells, E) & F) Cytotoxic T lymphocytes, CD8+ and B cell populations respectively. Evaluation of the various myeloid cell types extracted from the mice colon in distinctive treatment groups from the IELs, G) The target cell population, Ly6G+ and CD11b + cells are double positive neutrophils.H) Representative FACS panels are used to evaluate putative macrophages population (MHC-II+SiglecF+ myeloid cells) and I) The population of dendritic cells in IEL are defined as SiglecF- and MHC Class II+. J) Representative FACS plots for CD4+ helper T cells, K) & L) CD8+ cytotoxic population of T lymphocytes, and the presence B cells respectively. A′-L′) All FACS plots shown in supporting information Figure S9. Data represent cell numbers and ratios; provide a comparative picture of the distribution of immune cells in each of these compartments. M) Advancing UC in GALT (Gut-Associated Lymphoid Tissue) with M@D@Re-SCNPs therapy. In agreement with the previously described findings, we also a notable increase in the eosinophil proportion in the lamina propria and IEL isolated from colitis mice's colon tissue. When M@D@Re-SCNPs were given to these colitis mice, the percentages of eosinophils in IEL and lamina propria cells were much lower. A specific subset of tissue immune cell types, such as intestinal DCs and putative macrophage population are positioned effectively at the interfaces where the host and enteric luminal environment meet. They are ready to react to different dietary stimuli as well as microbes. More importantly, it has been shown by recent genomic-wide associated studies with the pathogenesis of IBD in general, and UC in particular, is impacted by intrinsic anomalies in the functioning of DCs and macrophages [42]. In IBD, intestinal DCs and macrophages are involved in poor microbe clearance, poor stimuli to enteric microbes, and hindered transitions from pro-to anti-inflammatory responses essential for resolution. Novel pathogenesis-based treatment strategies are being explored for human IBD as the processes by which intestinal macrophages and dendritic cells cause chronic inflammation become clearer [43]. Compared to healthy mice, DSS treatment in our investigation notably boosted the cell populations of the intestinal DC and putative macrophage population in both lamina propria and IEL cells. Compared to the control, the dendritic cell and putative macrophage population fractions were significantly reduced in the colitis mice treated with M@D@Re-SCNPs. Nevertheless, administering free rebamipide to colitis-induced mice did not result in favourable outcomes since this group's dendritic cells and macrophage populations did not alter. Compared to healthy individuals, there is a significant rise in the percentage of T lymphocytes' circulating CD4+ and CD8+ cells in people with IBD. IBD patients' plasma levels of interleukin-6 and C-reactive protein match the proportions of CD8+ T lymphocytes, which also show enriched for cells express CD38 and human leukocyte antigen (HLA)-DR [44]. Widespread inflammation and intestinal epithelium loss are hallmarks of ulcerative colitis (UC), and they are associated with specific risk single nucleotide variations in HLA class II. Considering the connections recently shown between some The functional importance of the genetic links between UC and HLA-DP haplotypes, as well as HLA-DP molecules and the NKp44 receptor, which makes NK cells active [45]. The HLA region and UC have a strong genetic association, suggesting that antigenic stimulation plays a significant role in the disease's genesis. Similarly, In comparison to healthy individuals, those who have IBD have higher populations of B cells in their intestines that are irritated. Interestingly, individuals with ulcerative colitis type 1 have increased BAFF (B cell activation factor) expression levels, indicating that B lymphocytes may have a part in IBD [46,47]. We examined the lymphocyte populations in our current investigation, including B cells, CD8+ cytotoxic T cells, and CD4+ helper T cells. It was shown that all of the lymphocytes displayed increased cell population in colitis mice, indicating the degree of inflammation. Colitis mice had much lower proportions of the inflammatory lymphocytes in the lamina propria and IEL when they received M@D@Re-SCNPs (Fig. 6D, E, 6F, and 6J, 6K, 6L) than the free rebamipide group and quantified in Fig. S8. The study demonstrates that M@D@Re-SCNPs exhibit a potential therapeutic effect on distinct myeloid cell populations inside the lamina propria and intraepithelial lymphocytes (IELs), contributing to the alleviation of dextran sulfate sodium (DSS)-induced ulcerative colitis by modulating local immune responses and promoting intestinal homeostasis as shown in Fig. 6M. This proves that this M@D@Re-SCNPs have potent anti-inflammatory therapeutic potential. Histological inflammation mitigation by M@D@Re-SCNPs in colitis mice The H&E staining [48,49] representative images revealed that the M@D@Re-SCNPs treated colitis animals had significantly reduced histological inflammation. Conversely, mice with colitis that were not treated (4% DSS group) or animals who received an identical dosage of free rebamipide and M@D@B-SCNPs showed histological damages such as impaired continuity of the mucosal epithelium lining, crypt destruction, interstitial inflammation, significant infiltration of pro-inflammatory cells, and partial erosion of the colonic epithelium layer or lamina propria. In the Hematoxylin and Eosin (H&E) stained colon sections, the DSS + M@D@B-SCNPs (without rebamipide) group demonstrated pronounced morphological damage compared to the other groups, particularly those treated with rebamipide-loaded lipid polymeric nanoparticles (M@D@Re-SCNPs), control, colitic mice, and free rebamipide groups. In the DSS + M@D@B-SCNPs group, there was significant epithelial disruption, crypt loss, and inflammatory cell infiltration, similar to the untreated colitic mice, indicating that the M@D@B-SCNPs lacked therapeutic effects. These changes were indicative of severe colonic injury and inflammation caused by DSS-induced colitis. In contrast, the M@D@Re-SCNPs group showed marked histological improvements, including preserving crypt structure, reducing inflammatory cell infiltration, and restoring the epithelial lining. The control group exhibited normal colon morphology, while the free rebamipide treated group demonstrated partial recovery with reduced histopathological damage. The differences observed under H&E staining highlighted the therapeutic role of rebamipide in mitigating colonic damage and inflammation, which was absent in the M@D@B-SCNPs group, reinforcing the importance of the rebamipide loaded nanoparticles, i.e. M@D@Re-SCNPs in protecting colon morphology (Fig. 7A). Goblet cells in the colon release a shielding mucin, and the devastation of these cells exacerbates the state of colitis. In colitis mice, populations of goblet cells were significantly reduced, evidenced by Alcian blue staining. The preservation of goblet cells was enhanced by free rebamipide therapy, whereas the mucin integrity was compromised. M@D@Re-SCNPs showed more goblet cells and an undamaged, continuous mucin lining (blue stain), which suggested enhanced protection against damage to the colonic crypt and preserved integrity of the gut epithelium (Fig. 7B). Sulfomucin and sialomucin are the two forms of mucins that goblet cells produce. Research has indicated that gut inflammation is linked to increased sialomucin production, whereas healthy mucosal mostly secretes sulfomucin [50,51]. Goblet cell-produced sulfomucin (brown stain) and sialomucin (blue stain) were distinguished by HID-AB staining. Regular colons had higher amounts of sulfomucin, whereas colitis tissues had greater amounts of sialomucin. Free Rebamipide increased the release of sulfomucin, whereas M@D@Re-SCNPs showed a noteworthy and higher augmentation of sulfomucin in colitis mice. Sulfomucin levels were higher than sialomucin levels, primarily in healthy control and without rebamipide (M@D@B-SCNPs) groups without DSS. The study findings indicate that M@D@Re-SCNPs have shown more effectiveness in causing the production of sulfomucin, highlighting its ability to protect the integrity of the intestinal barrier in colitis mice by boosting healthy mucin (Fig. 7C). Colitis has been seen to have mast cell infiltration in the layers of the submucosal of the inflammatory colon. Histamine is released at the inflammation site due to mast cell activation driven on by this invasion [52]. Consequently, histamine actively mediates alterations caused by inflammation through cellular and humoral pathways. Infiltration of mast cells within the region of inflamed colon, a hallmark of the colitis, was shown by toluidine blue (TB) staining. Activation of mast cells occurred in the submucosal layer of the colitis colon tissue, while they didn't appear at healthy and M@D@B-SCNPs groups animal and M@D@Re-SCNPs (Fig. 7D). M@D@Re-SCNPs proficiently averted mast cell infiltration and alleviated inflammatory alterations in the colitis. ) M@D@Re-SCNPs reduction of histopathological inflammation in mice with colitis: A) Representative H&E staining micrographs showed that histological inflammation was reduced in colitis animals those receiving PBS (Control), M@D@Re-SCNPs, naïve rebamipide; however, both mice that treated M@D@B-SCNPs and mice with colitis that received no therapy had histological damage. M@D@B-SCNPs exhibited histological damages, impaired continuity of the mucosal epithelium lining, crypt destruction, interstitial inflammation, significant infiltration of pro-inflammatory cells, and partial erosion of the colonic epithelium layer or lamina propria. M@D@Re-SCNPs-mediated mitigation of mucin degradation and Inflammation in Colitis mice B) Alcian blue-neutral red (AB-NR) staining; The control and M@D@Re-SCNPs group (black asterisks) both had an undisturbed mucin lining as visible via blue color stain, although the mucin layer was diminished in colitis mice (DSS) as well as M@D@B-SCNPs + DSS group. In rebamipide group's mucin content was restored, however not to the same extent as with M@D@Re-SCNPs treatment. C) High Iron Diamine and Alcian Blue (HID-AB) staining- M@D@Re-SCNPs exhibited increased efficacy in sulfomucin induction than free rebamipide. D) Toluidine blue (TB) staining- Mast cell infiltration was noted in the inflamed colon of colitis brought on by DSS, and DSS + M@D@B-SCNPs (marked by arrowhead) as M@D@Re-SCNPs showed no signs of the mast cells (Scale bar 50 μm, magnification 40X). M@D@Re-SCNPs alleviate the signs associated with colitis by reducing innate immune reactions The two general categories of macrophage activation are proinflammatory (M1) and anti-inflammatory (M2) polarisation [53] as well as macrophages, which express a wide range of chemokines and cytokines, are necessary to keep the mucosa in a healthy state. [42]. Many investigations emphasize the importance of the NF-κB pathway in suppressing the synthesis of cytokines in UC individuals. Furthermore, the NF-κB pathway is essential to immunological responses and gastrointestinal inflammation. Extensive colonic inflammation reactions are caused by an excess of cytokines (proinflammatory) and inadequate levels of anti-inflammatory agents. Interestingly, NF-κBp65 is elevated in a number of cellular levels in UC individuals, such as intestine mucosal epithelium, lamina propria monocytes, and crypt epithelial cells. In the nucleus, NF-κBp65 expression is noticeably more important than in the cytoplasm. In the pathophysiology of UC, interleukin-1 beta (IL-1β), nuclear factor erythroid 2–related factor 2 (Nrf2), phosphoinositide 3-kinase (PI3K), peroxisome proliferator-activated receptor-gamma (PPAR-γ), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), human macrophage inflammatory protein-1 alpha (MIP-1α) play a pivotal role as inflammatory mediators and have been traced to the severity and advancement of the illness in UC. According to immunohistochemistry investigations, colitis scenarios had more significant factors of inflammation, including NF-κB, COX-2, IL-1β, Nrf2, PI3K, MIP-1α, and iNOS levels. Contrarily to free rebamipide and M@D@B-SCNPs, the M@D@Re-SCNPs therapy showed a marked reduction in the number of NF-κB, COX-2, IL-1β, Nrf2, PI3K, MIP-1α, and iNOS cells (Fig. 8A). Specific columnar epithelium cells called goblet cells play a key role in the release of mucin, which produces glycoproteins with high molecular weights that are necessary for the epithelium's defense towards inflammation, infections, and luminal stimuli [19]. The gut mucus main constituent, MUC2, acts as a barrier to protect the epithelium. Changes in goblet cell function, such as their absence or decrease, are a contributing factor to intestinal inflammation in IBD [54]. MUC2 is the primary intestinal mucin that stops preventing the migration of microbes from entering within the intestine. Intestinal epithelial cells stay in close contact with bacteria due to MUC2 deficiency, which triggers inflammation and the immune system [55]. Regarding the immune response and intestinal architecture, it has been shown that the MUC2 deletion in the mouse model faithfully mimics the intestinal inflammation associated with IBD [56]. In addition to mucin glycoproteins, goblet cells also release MUC5B along with MUC2. Immunohistochemical observation demonstrated that in the severe colitis group, MUC2 and MUC5B expression was either nonexistent or insignificant, yet M@D@Re-SCNPs therapy restored both MUC2 and MUC5B more than rebamipide treatment. By regulating the intestinal mucin's balance, this rebamipide reduces inflammation (Fig. 8A). The therapeutic potential of M@D@Re-SCNPs in DSS-induced colitis was evaluated through comparative macroscopic, histopathological and immunohistochemical evaluation. The profound colon shortening, disruption of the epithelium, inflammatory cell infiltration, depletion of goblet cells, disruption of mucin distribution, and increased expression of inflammatory biomarkers in DSS-treated mice all suggested a significant degree of injury to the colon and inflammation of the mucosa. H&E, AB-NR, HID-AB and toluidine blue staining analyses showed that treatment with M@D@Re-SCNPs significantly restored colon length and improved overall architecture of the colon. In addition, immunohistochemical evaluation showed that M@D@Re-SCNPs treatment resulted in significant reduction in pro-inflammatory markers, as well as in mucosal protection and tissue recovery. Notably, the therapeutic outcomes with M@D@Re-SCNPs were found to be similar to that of the clinically established 5-ASA treatment group, further solidifying the translatability of the developed oral nanoformulation for therapeutic application in the treatment of IBD (Figs. S5-S7). For the IHC indicators, a quantitative evaluation of immunopositive cells was carried out. This study provides strong evidence of the effective anti-inflammatory effects of employing M@D@Re-SCNPs nanotherapeutics in place of rebamipide (Fig. S8). ) M@D@Re-SCNPs alleviates the signs associated with colitis by reducing innate immune reactions. A) Immunohistochemistry regulators namely NF-κB, IL-1β, Nrf2, PI3K, PPARγ, COX-2, iNOS, MIP-1α demonstrated proinflammatory mediator inhibition and controlled the healing of, MUC2 and MUC5B.(Scale bar 50 μm, magnification 40X). In the colitis condition, colonic tissues showed upregulation of inflammatory markers including NF-κB, IL-1β, Nrf2, PI3K, PPARγ, COX-2, iNOS, and MIP-1α, alongside downregulation of mucosal barrier components MUC2 and MUC5B. Treatment with M@D@Re-SCNPs significantly reduced the expression of proinflammatory cytokines and signaling molecules, while restoring the expression of protective mucins, indicating effective mitigation of colitis and promotion of mucosal healing. B) In mice with colitis, M@D@Re-SCNPs therapy reduces inflammatory cytokines. a) MPO level, b) nitrite levels, c) TNF-α and d) IL-1β. The results were presented as mean ± SD, ns-non significant I, N = 6 ∗/#p ≤ 0.05; ∗∗/##p ≤ 0.01; and ∗∗∗/###p ≤ 0.001, respectively. M@D@Re-SCNPs therapy reduces inflammatory cytokine levels We evaluated the therapeutic efficiency of M@D@Re-SCNPs by assessing key anti-inflammatory markers, including myeloperoxidase (MPO), nitrite, TNF-α, and IL-1β. The results demonstrated a significant reduction in MPO activity, nitrite production, and levels of pro-inflammatory cytokines TNF-α, and IL-1β, in M@D@Re-SCNPs treated samples, highlighting their potential to mitigate inflammation and confirming their therapeutic efficacy. The granulates of neutrophils and monocytes contain the glycosylated enzyme myeloperoxidase (MPO). It acts as a indicators to determine an IBD [57]. Treatments using M@D@Re-SCNPs and free rebamipide significantly decreased MPO activity (Fig. 8B a), a neutrophil infiltration marker. Significantly elevated MPO level was seen in the tissue of colitis mice, indicating increased infiltration of neutrophils. The MPO levels in both the control and M@D@B-SCNPs groups were perpetually low. M@D@Re-SCNPs treatment significantly decreased the level of nitrite (Fig. 8B b), as well as the production of proinflammatory cytokines, such as TNF-α (Fig. 8B c) and IL-1β (Fig. 8B d) in colitis mice exhibiting excellent anti-inflammatory capabilities. When compared to free rebamipide, M@D@Re-SCNPs showed a greater therapeutic effect on colitis. The M@D@Re-SCNPs treated group shows a more pronounced suppression of inflammatory cytokine expression and a significant reduction in immune cell infiltration, reflecting enhanced anti-inflammatory effects. This improvement likely results from the sustained and targeted delivery of rebamipide by the nanoparticles, leading to better control of the inflammatory cascade. The superior performance of M@D@Re-SCNPs in reducing innate immune activation and cytokine levels compared to free rebamipide underscores the efficacy of nanocarrier systems i.e. lipid polymeric nanoparticles in enhancing therapeutic outcomes. Safety evaluation of M@D@Re-SCNPs treatment When developing new nanomedicine or new drug delivery systems, investigators are always quite worried about the possible toxicological consequences of nanomaterials during therapy [58]. The liver histological sections from the DSS + M@D@Re-SCNPs group and the Control + M@D@B-SCNPs group exhibited well preserved tissue architecture, indicating overall normal hepatic health. Hepatocytes in liver sections showed typical sizes and shapes without aberration, and after treatment, no infiltration of inflammatory cells was seen, nor were there any vascular abnormalities. Kidney sections H&E stained, tubules were intact with typical dimensions and shape. There were no signs in the glomerular tufts of inflammation or cellular infiltration, confirming the renal cortex general state of health. The histoarchitecture of spleen segments was entirely normal and healthy, with preserved lymphoid follicles and without inflammatory cell influx. Additionally, the histological analysis of the heart of mice in the Control (healthy) groups, DSS + M@D@Re-SCNPs (final treatment) and Control + M@D@B-SCNPs (without rebamipide) group revealed integrated and normal myofibrils without infiltration of cells or any signs of nuclear or cytoplasm disintegration. Owing to their vital blood supply, the lungs belong to the organs prone to the harmful effects of nanomedicine. Control groups, DSS + M@D@Re-SCNPs and Control + M@D@B-SCNPs treatment showed no evidence of inflammation or damage, comprehensive alveolar structures, comparatively intact bronchiolar epithelia, and preserved alveolar frameworks, all of which were indicative of normal lung conditions (Fig. 9). This elucidated that M@D@Re-SCNPs formulation is safe for treating IBD as it did not adversely affect the histoarchitecture of vital organs. M@D@Re-SCNPs therapy for toxicological assessment: Photomicrographs showing mouse-isolated heart, kidney, liver, lungs, and spleen sections stained with H&E of Control (healthy) groups, DSS + M@D@Re-SCNPs(final treatment) and Control + M@D@B-SCNPs (without rebamipide) group (N = 3×, 40× magnification). Conclusion In this study, we successfully developed a multifunctional oral nanoparticle platform (M@D@Re-SCNPs) for the targeted treatment of ulcerative colitis. The formulation combines gastroprotective mucin coating with a mucoadhesive DEAE-dextran layer and encapsulated rebamipide within a 6-O-stearoyl ascorbic acid and caprylic acid-based core. This system demonstrated strong gastric resistance, targeted adhesion to inflamed colonic mucosa, and extended gastrointestinal retention. In vivo studies in a DSS-induced colitis mouse model revealed that M@D@Re-SCNPs significantly enhanced therapeutic outcomes compared to free rebamipide, including suppression of pro-inflammatory pathways (NF-κB, PI3K/AKT), upregulation of antioxidant signaling via PPAR-γ, and restoration of mucosal integrity through MUC2 expression. These findings highlight the potential of M@D@Re-SCNPs as a safe, effective, and targeted strategy for managing inflammatory bowel disease and potentially other gastrointestinal disorders. Ethics statement The Indian Institute of Science Education and Research, Mohali (IISER Mohali), the Committee for Purpose of Control and Supervision on Experimental Animals (CPCSEA), India, has granted it full accreditation, approved the use of animals in all of its experiments. The project number for approval is IISERM/SAFE/PRT/2023//008. CRediT authorship contribution statement Chandrashekhar Jori: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. Anas Ahmad: Data curation, Formal analysis, Investigation, Methodology. Ajay Kumar: Data curation, Formal analysis, Investigation, Methodology. Nemat Ali: Formal analysis, Investigation, Methodology. Young-Ok Son: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Writing – review & editing. Rehan Khan: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments This work was supported by theIndian Council of Medical Research (ICMR) (Grant Numbers: FIW-2025-01-00000682 and FIW2025-01-00001184), Department of Health Research, Grant in AID (Grant No. R.11017/23/2023-GIA/HR), Department of Science and Technology (DST), ANRF (Grant No. ANRF/ARG/2025/005584/LS) and CCRUM, Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy (AYUSH), Government of India. TECH-21/4/2025-CCRUM-HQ. CJ acknowledges Institute of Nano Science Technology, for providing fellowship. This work was supported by the Basic Science Research Program of the Research Institute for Basic Sciences (RIBS) of the Jeju National University through the National Research Foundation (NRF), funded by the Ministry of Education (Grant No.RS-2019-NR040080). The authors acknowledge and appreciate the Ongoing Research Funding Program, (ORF-2026-940) King Saud University, Riyadh, Saudi Arabia. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.mtbio.2026.103322. Contributor Information Young-Ok Son, Email: sounagi@jejunu.ac.kr. Rehan Khan, Email: rehankhan@inst.ac.in. Supplementary data The following is/are the supplementary data to this article: Multimedia component 1 Data availability Due to confidentiality of the data, it is available only upon valid request from the corresponding author. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement Due to confidentiality of the data, it is available only upon valid request from the corresponding author.